Stockreport

ImmunityBio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA® in BCG-Unresponsive Papillary Bladder Cancer [Yahoo! Finance]

ImmunityBio, Inc.  (IBRX) 
PDF to potentially support a resubmission of the sBLA for BCG-unresponsive papillary NMIBC The additional information does not include the initiation or design of any new [Read more]